Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|July 4, 2006
[Stenting central airways with tracheobronchial stents]Robert M Mróz, Elzbieta Chyczewska
Advances in Medical Sciences|March 19, 2025
Characteristics of patients with severe asthma reported to be eligible or non-eligible for biologic therapy in Poland: Results from the international observational study RECOGNISERobert M Mróz, Łukasz Minarowski, Jolanta Biegalska
Advances in Experimental Medicine and Biology|April 22, 2018
Estimates of Medication Expenditure for Ischemic Heart Disease Accompanying Chronic Obstructive Pulmonary DiseaseEdyta Rysiak, Izabela Prokop, Ilona Zaręba, et al.
Journal of Clinical Medicine|November 25, 2023
Non-Invasive Cardiac Output Measurement Using Inert Gas Rebreathing Method during Cardiopulmonary Exercise Testing-A Systematic ReviewAgnieszka Chwiedź, Łukasz Minarowski, Robert M Mróz, et al.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|May 2, 2006
[Pathogenesis of chronic obstructive pulmonary disease. Cellular mechanisms (part I)]Robert M Mróz, Patryk Szulakowski, Wliadysław Pierzchala, et al.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|July 4, 2006
[Pathogenesis of chronic obstructive pulmonary disease. Molecular mechanisms (part II)]Patryk Szulakowski, Robert M Mróz, Władysław Pierzchała, et al.
Pneumonologia I Alergologia Polska|April 25, 2003
[Comparison of cellular composition of induced sputum, bronchial washings and bronchoalveolar lavage fluid in sarcoidosis, hypersensitivity pneumonitis and COPD]Robert M Mróz, Elzbieta Chyczewska, Małgorzata Korniluk, et al.
Pneumonologia I Alergologia Polska|December 31, 2010
[Treatment of chronic obstructive pulmonary disease--traditional bronchodilatation and targeted anti-inflammatory therapy]Robert M Mróz, Tomasz Skopiński, Adam Hołownia, et al.
Advances in Medical Sciences|March 14, 2023
Genome-engineering technologies for modeling and treatment of cystic fibrosisMichał Dębczyński, Damian Mojsak, Łukasz Minarowski, et al.
The Lancet. Respiratory Medicine|April 5, 2026
Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 studyJorge F Maspero, Ian D Pavord, Michael E Wechsler, et al.
Pageof 2